important contributor to the pathogenesis of EH, for example, hypomethylation of interleukin-6 (IL-6), 6 angiotensin II type 1 receptor (AGTR1), 7 angiotensin-converting enzyme (ACE), 8 Na+/K+/Cl− cotransporter protein 1 (NKCC1), 9 and α-adducin (ADD1), 10 and the hypermethylation of 11β-hydroxysteroid dehydrogenase type II (11β-HSD-2).
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Serine hydroxymethyltransferase 1 (SHMT1), located on chromosome 17p11.2, is a key enzyme involved in folic acid metabolism.
SHMT1 reversibly catalyzes the conversion of serine and tetrahydrofolate to glycine and 5, 10-methylenetetrahydrofolate (5, 10-methyleneTHF). 12 Besides, it also plays a key role in inducing gene methylation and DNA synthesis by providing one-carbon units for purine, thymidylate, and methionine. 12 The one-carbon moiety of 5, 10-methyleneTHF is in turn directed to the synthesis of purines or thymidylate or to the methionine cycle, where it remethylates homocysteine (Hcy) to synthesize methionine and S-adenosyl methionine. Low levels of SHMT1 enzyme resulted in decreased levels of 5-methylTHF, which is a cosubstrate for the conversion of Hcy to methionine, 13 and low levels of 5-methylTHF in turn resulted in increased levels of Hcy, which is a well-known risk factor for hypertension. 14 Based on these results taken together, we hypothesized that SHMT1 promoter hypermethylation might contribute to the development of hypertension.
Therefore, here, we aimed to investigate the association between SHMT1 promoter hypermethylation and EH in an age-and gender-matched case-control study. We also performed a data mining analysis to verify the relationship between SHMT1 promoter hypermethylation and SHMT1 gene expression.
| MATERIAL S AND ME THODS

| Study participants
We enrolled 241 EH patients and 288 age-and gender-matched non-EH individuals who were all Chinese, aged either 18 years or older, and lived in the Nanshan District (Shenzhen, China) community for at least 6 months. 
| Biochemical measurements
Glucose (Glu), total cholesterol (TC), triglyceride (TG), low-density lipoprotein (LDL), uric acid (UA), and plasma homocysteine (Hcy) levels were measured. Uric enzyme method was performed for quantitative determination of uric acid levels. TC, TG, LDL, and Glu levels were determined by the enzymatic method, and Hcy level was determined by the circulating enzyme method. All these biological indicators were measured using an automatic biochemical analyzer (HITACHI 7080; Tokyo, Japan).
| DNA methylation analysis
The isolation and quantification of genomic DNA were performed using a Nucleic Acid Extraction Kit (TIANLONG NP968, Xi'an, China) and a NanoDrop 2000 (Thermo Scientific, Wilmington, DE, USA).
Sodium bisulfite modification was performed using the EZ DNA 
| Luciferase reporter gene assay
The amplified promoter DNA fragment was digested with XhoI and NheI (New England Biolabs, Ipswich, MA, USA). After being purified using a Cycle-Pure Kit (Omega, Norcross, GA, USA), the target city, WI, USA), using a DNA Ligation Kit (Takara, Kusatsu, Japan).
Luciferase activity was determined using the dual-luciferase reporter assay system (Dual-Luciferase® Reporter Assay Systems, Promega). Youden index, and the area under the ROC curve (AUC) was used to evaluate the diagnostic value of SHMT1 methylation for hypertension. The cutoff value was used to distinguish hypermethylation from hypomethylation. Bilateral P < 0.05 was considered to indicate statistically significant differences. All statistical analyses were performed using the SPSS 18.0 software (SPSS, Inc, Somers, NY, USA).
| Statistical analysis
| RE SULTS
A fragment in the SHMT1 promoter island (hg19, Chr17:
18 266 824-18 266 911) was selected for the methylation assay ( Figure 1A) . Sequencing of the qMSP product showed successful bisulfite conversion of the template DNA ( Figure 1B) . Further, capillary electrophoresis confirmed that the qMSP-amplified fragment was 88 bp in length ( Figure 1C ). We observed statistically significant differences in LDL and Glu levels, BMI, SBP, DBP, and alcohol consumption between the cases and controls (Table 2) , and the average Hcy level was 15.33 μmol/L in the case group, which was higher than 13.90 μmol/L in the control group (P = 0.005). There were no significant differences in age; gender; UA, TG, TC, and waist-hip rate (WHR) levels; and smoking status between the cases and controls.
As shown in Figure 2 , SHMT1 promoter methylation levels were significantly higher in the 241 EH patients than in the 288 age-and promoter methylation than their counterparts. In addition, SHMT1
promoter methylation was not associated with gender, BMI, and LDL and Glu levels ( Table 3 ). The diagnostic value of SHMT1 promoter methylation was shown in Figure 3 , with AUC and 95% CI being 0.808 (0.771-0.846), and sensitivity and specificity being 73.9% and 77.8%, respectively.
We further analyzed SHMT1 expression in the carotid endothelium (LCA and RCA) with and without 5-AZA treatment (Accession No. GSE56143). The expression level of SHMT1 in the RCA was significantly increased after demethylation by 5-AZA (P = 0.028, Figure 4A ). The data indicated that higher levels of SHMT1 promoter methylation reduced SHMT1 expression. Subsequently, we also performed dual-luciferase reporter assays to check whether the SHMT1 CpG island region could regulate gene expression. Our results showed that the transcriptional activity of the recombinant 
TA B L E 2 Baseline characteristics between cases and controls
F I G U R E 2
Comparison of methylation level of SHMT1 between different subgroups. The methylation levels of SHMT1 are represented as median and interquartile range pGL3-SHMT1 plasmid was higher than that of the empty vector pGL3 basic (mean: 1.39 vs 0.02, fold change = 70, P = 0.003, Figure 4B ).
| D ISCUSS I ON
In this age-and gender-matched case-control study, SHMT1 promoter methylation levels were higher in EH patients than in healthy controls. The risk of SHMT1 promoter hypermethylation was significantly higher in both hyperhomocysteinemia and older groups.
The AUC was 0.808, with a sensitivity and specificity of 73.9% and 77.8%, respectively, suggesting that SHMT1 promoter hypermethylation is a potential biomarker for EH. In addition, data from our GEO analysis showed an inverse regulatory association between SHMT1 promoter methylation and SHMT1 expression. Dual-luciferase reporter assays indicated that the SHMT1 promoter plays an important regulatory role in its gene expression.
It is known that SHMT1 plays a key role in inducing gene methylation and DNA synthesis. 12 Our study demonstrated significantly increased SHMT1 promoter methylation levels in the EH patients.
The higher SHMT1 promoter methylation might have led to lower expression of the SHMT1 enzyme, which resulted in the decreased glycine levels, further restricting the production of glutathione. 18 As an estimator of oxidative stress, glutathione accelerates the development of hypertension. 18 Besides, low expression of SHMT1 might The methylation level of SHMT1 ≥15.67% was considered as hypermethylation and <15.67% was considered as hypomethylation. BMI, body mass index; EH, essential hypertension; Glu, blood glucose; Hcy, plasma homocysteine; LDL, low-density lipoprotein.
F I G U R E 3 Receiver operating characteristic (ROC) curve for the diagnostic value of SHMT1 methylation. The area under the curve (AUC) of SHMT1 methylation in patients with hypertension was 0.808 (0.771, 0.846), with sensitivity and specificity being 73.9% and 77.8%, respectively result in high levels of Hcy, thus contributing to the development of hypertension.
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Hyperhomocysteinemia is a well-known risk factor for EH. 19 A previous meta-analysis suggested that elevated Hcy levels increased the risk of EH by about an additional 36%. 20 In a prospective cohort study, the highest tertile of Hcy levels showed a 2.31-fold increased risk of hypertension. 21 Further, significant positive association between SHMT1 promoter methylation and high Hcy level was observed;
higher Hcy level showed a 1.90-fold increased risk of higher SHMT1 promoter methylation. Therefore, SHMT1 promoter hypermethylation may exert its effects on the risk of EH via regulating the levels of Hcy.
14 In our study, increased SHMT1 promoter methylation was associated with older age. Participants older than 65 years had a 1.46-fold increased risk of higher SHMT1 promoter methylation. Consistent with our study, previous studies also indicated a positive association between increased DNA promoter methylation, such as that for ADD1 22 and LINE-1, 23 and older age. Changes in DNA methylation may be induced by aging and environmental exposures. 24, 25 Notably, smoking and drinking are also important risk factors for hypertension, 27, 28 and both interact with DNA methylation of genes to affect the risk of EH. 7, 30, 31 However, we did not observe any significant interactions in our study, although future studies with larger sample size are needed to confirm our findings.
The following limitations of our study should be acknowledged.
First, we did not measure SHMT1 expression in our study participants. Alternatively, we used data from GEO and found an inverse correlation between SHMT1 methylation and expression. Second, owing to the nature of our case-control study, we could not determine the causality between SHMT1 promoter hypermethylation and EH. Third, the underlying mechanism of SHMT1 promoter hypermethylation in EH remains unclear. In addition, we cannot completely exclude the influence of other genes on folic acid metabolism.
Finally, we also did not measure the folic acid level; the relationship between SHMT1 promoter methylation and folic acid was therefore not explored in our study. To the best of our knowledge, this is the first age-and gender-matched case-control study to investigate the relationship between SHMT1 promoter methylation and EH.
In summary, SHMT1 promoter methylation is significantly correlated with homocysteinemia and age, and its hypermethylation increases the risk of EH SHMT1 promoter hypermethylation may therefore be a promising biomarker for diagnosing EH.
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